Texas measles cases rise to 146 in an outbreak that led to a child's death
DALLAS — The number of people with measles in Texas increased to 146 in an outbreak that led this week to the death of an unvaccinated school-age child, health officials said Friday.
The number of cases increased by 22 since Tuesday in Texas' largest outbreak in nearly 30 years. The Texas Department of State Health Services said cases span over nine counties in West Texas, including almost 100 in Gaines County, and 20 patients have been hospitalized so far.
The child who died Tuesday night in the outbreak is the first U.S. death from the highly contagious but preventable respiratory disease since 2015, the U.S. Centers for Disease Control and Prevention said. The child was treated at Covenant Children's Hospital in Lubbock, though the facility said the patient didn't live in Lubbock County.
Robert F. Kennedy Jr., the nation's top health official and a vaccine critic, said this week that the U.S. Department of Health and Human Services was watching cases but dismissed the outbreak as 'not unusual.'
The virus has largely spread through rural, oil rig-dotted West Texas, with cases concentrated in a 'close-knit, undervaccinated' Mennonite community, state health department spokesperson Lara Anton has said.
Gaines County has a strong homeschooling and private school community. It also is home to one of the highest rates of school-age children in Texas who have opted out of at least one required vaccine, with nearly 14% skipping a required dose last school year.
Texas law allows children to get an exemption from school vaccines for reasons of conscience, including religious beliefs. Anton has said the number of unvaccinated kids in Gaines County is likely significantly higher because homeschooled children's data would not be reported.
The measles, mumps and rubella (MMR) vaccine is safe and highly effective at preventing infection and severe cases of disease. The first shot is recommended for children ages 12 to 15 months, and the second for ages 4 to 6 years. Most kids will recover from measles, but infection can lead to dangerous complications such as pneumonia, blindness, brain swelling and death.
Vaccination rates have declined nationwide since the COVID-19 pandemic, and most states are below the 95% vaccination threshold for kindergartners — the level needed to protect communities against measles outbreaks.
The U.S. had considered measles, a respiratory virus that can survive in the air for up to two hours, eliminated in 2000, which meant there had been a halt in continuous spread of the disease for at least a year. Measles cases rose in 2024, including a Chicago outbreak that sickened more than 60.
Eastern New Mexico has nine cases of measles currently, but the state health department said there is no connection to the outbreak in West Texas.
Stengle writes for the Associated Press.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
2 hours ago
- Politico
WHO sounds the alarm as US measles cases mount
Presented by Driving The Day WHO SPEAKS UP ON MEASLES — President Donald Trump might not care for the World Health Organization's advice, but that isn't stopping one of its top officials from warning his administration about what's at stake as measles cases accumulate in the U.S. Dr. Katherine O'Brien, the WHO's vaccines director, told POLITICO's Carmen Paun that U.S. political leaders should clearly endorse and promote measles vaccination to prevent the country from losing its disease-elimination status — and become a location that gives rise to future outbreaks that can easily spread domestically and abroad among travelers. If the disease spreads continuously for a year, it would be considered endemic for the first time in 25 years. 'It's really a sign of a country going backwards in terms of their ability to protect people,' O'Brien said. Why it matters: O'Brien said 'leadership voices really matter' when people consider medical interventions for their children. If one family is influenced enough to decline the measles, mumps and rubella vaccine for their child, that's 'one child too many,' she said, given how highly contagious the virus is. Measles is 'not just a fever and a rash that people get over,' O'Brien said. So far this year, three unvaccinated people — including two young girls — have died from the disease in the U.S. Before the most recent outbreak, the last U.S. measles death occurred in 2015. Background: HHS Secretary Robert F. Kennedy Jr. has couched his promotion of the MMR shot with statements emphasizing that vaccination is a personal choice. Before he ran for president and then entered government, Kennedy founded Children's Health Defense, an anti-vaccine nonprofit that suggests shots cause a slew of pediatric medical problems such as autism, asthma and developmental delays. Kennedy has also inaccurately asserted that the MMR vaccine contains cells from aborted fetuses and has touted supplements like vitamin A as a disease treatment. HHS has defended the secretary's measles response, calling 'claims' that he's 'spreading misinformation or undermining vaccine confidence … flat-out false.' WELCOME TO FRIDAY PULSE. I'm FDA reporter Lauren Gardner, filling in for Kelly today. Pass along your tips, scoops and feedback to lgardner@ and khooper@ and follow along @Gardner_LM or @Kelhoops. POLITICO PRO SPACE — Need an insider's guide to the politics behind the new space race? From battles over sending astronauts to Mars to the ways space companies are vying to influence regulators, this weekly newsletter decodes the personalities, policy and power shaping the final frontier. Find out more. In Congress THIRD RAIL NO MORE? Senate Republicans are considering ways to incorporate Medicare cuts into their domestic spending package to help offset its cost — a move that could divide a party that can't afford many defections to pass the president's signature legislation, POLITICO's Jordain Carney, Meredith Lee Hill and Robert King report. The House version of President Donald Trump's big beautiful bill includes cuts to Medicaid, the government health insurance program for low-income people and those with disabilities. But cuts to Medicare — which insures those 65 and older — are widely seen as politically dangerous. The idea percolated in private meetings this week as GOP leaders try to placate budget hardliners who want more spending cuts in the package ahead of a self-imposed July 4 deadline for passage. And some Republicans believe Trump supports Medicare cuts — provided they're limited to targeting 'waste, fraud and abuse' — despite the potential for backlash from rank-and-file senators and House moderates who already sank efforts to touch the program. HEADING TO THE HUMPHREY BUILDING — The Senate confirmed Jim O'Neill on Thursday in a 52-43 vote to be HHS's deputy secretary, your morning host writes. O'Neill, a George W. Bush-era HHS official who's close with early Trump supporter and tech billionaire Peter Thiel, will be the department's No. 2 official charged with managing operations. AROUND THE AGENCIES FDA'S RARE DISEASE DRUG APPROACH — The FDA's leading biologics regulator said Thursday that he was open to using alternative measurement methods when evaluating rare-disease therapies, combining what he called 'gold-standard science and common sense' in the approval process. 'We will rapidly make available therapies at the first sign or promise of biomedical success or action, but we're also going to follow up overall survival and quality of life on the back end,' Dr. Vinay Prasad, director of the FDA's Center for Biologics Evaluation and Research, said during an agency roundtable on cell and gene therapies. The remarks were notable given Prasad's history of criticizing past FDA approvals of certain treatments, including a controversial Duchenne muscular dystrophy gene therapy and certain cancer drugs, using surrogate markers. Prasad added he's often asked whether he's 'solely' interested in randomized controlled trials and said he's open to a variety of methodologies demonstrating a drug's benefit. Background: His remarks come weeks after he and Commissioner Marty Makary unveiled a new Covid-19 vaccine framework that limits approvals of future formulation changes to people 65 and older and younger individuals with an underlying condition — and requiring new RCTs to prove the shots are safe and effective for young, healthy people. Cell and gene therapies are often discussed in the context of rare diseases as the technologies can address root causes instead of solely managing symptoms. But a condition's rarity hinders a company's ability to conduct a large-scale trial for a drug candidate, an issue with which regulators and industry have long struggled. The FDA launched a rare disease 'hub' last year to better align its drug and biologics regulators in their approach to considering those therapies for the market. NIH LOOKS TO AI — The National Institutes of Health is building an AI strategy to help HHS Secretary Robert F. Kennedy Jr. target chronic disease, POLITICO's Ruth Reader reports. Principal Deputy Director Matthew Memoli announced the plan Thursday, asking the public to weigh in at the Coalition for Health AI's Innovation Summit at Stanford University. NIH wants industry to comment on both the broad approach and the specific actions the administration should take in developing the strategy. The agency plans to create a new website to highlight its AI work. 'Addressing this crisis is going to require large-scale efforts — research that's going to generate large amounts of data — and we are going to need all the tools available to us in order to try to address this,' Memoli said. Names in the News Courtney Rhodes is now head of news and media relations at the U.S. Travel Association. She was previously a spokesperson at the FDA. The Health Resources and Services Administration announced its new 34-member board of directors for the Organ Procurement and Transplantation Network. WHAT WE'RE READING House FDA appropriators advanced their fiscal 2026 spending measure Thursday for the agency and the U.S. Department of Agriculture, POLITICO's David Lim reports. Infectious disease and other medical experts fear HHS's changes to Covid-19 vaccine recommendations will make it more difficult to immunize people by complicating discussions with providers and likely leading to fewer places stocking them, Stat's Helen Branswell writes.
Yahoo
2 hours ago
- Yahoo
In axing mRNA contract, Trump delivers another blow to US biosecurity, former officials say
This is a KFF Health News story. The Trump administration's cancellation of $766 million in contracts to develop mRNA vaccines against potential pandemic flu viruses is the latest blow to national defense, former health security officials said. They warned that the U.S. could be at the mercy of other countries in the next pandemic. "The administration's actions are gutting our deterrence from biological threats," said Beth Cameron, a senior adviser to the Brown University Pandemic Center and a former director at the White House National Security Council. "Canceling this investment is a signal that we are changing our posture on pandemic preparedness," she added, "and that is not good for the American people." Flu pandemics killed up to 103 million people worldwide last century, researchers estimate. MORE: Bird flu is continuing to spread in animals across the US. Here's what you need to know In anticipation of the next big one, the U.S. government began bolstering the nation's pandemic flu defenses during the George W. Bush administration. These strategies were designed by the security council and the Biomedical Advanced Research and Development Authority at the Department of Health and Human Services, among other agencies. The plans rely on rolling out vaccines rapidly in a pandemic. Moving fast hinges on producing vaccines domestically, ensuring their safety and getting them into arms across the nation through the public health system. The Trump administration is undermining each of these steps as it guts health agencies, cuts research and health budgets and issues perplexing policy changes, health security experts said. Since President Donald Trump took office, at least half of the security council's staff have been laid off or left, and the future of BARDA is murky. The nation's top vaccine adviser, Peter Marks, resigned under pressure in March, citing "the unprecedented assault on scientific truth." Most recently, Trump's clawback of funds for mRNA vaccine development put Americans on shakier ground in the next pandemic. "When the need hits and we aren't ready, no other country will come to our rescue and we will suffer greatly," said Rick Bright, an immunologist and a former BARDA director. Countries that produced their own vaccines in the COVID-19 pandemic had first dibs on the shots. While the United States, home to Moderna and Pfizer, rolled out second doses of mRNA vaccines in 2021, hundreds of thousands of people in countries that didn't manufacture vaccines died waiting for them. The most pertinent pandemic threat today is the bird flu virus H5N1. Researchers around the world were alarmed when it began spreading among cattle in the U.S. last year. Cows are closer to humans biologically than birds, indicating that the virus had evolved to thrive in cells like our own. As hundreds of herds and dozens of people were infected in the U.S., the Biden administration funded Moderna to develop bird flu vaccines using mRNA technology. As part of the agreement, the U.S. government stipulated it could purchase doses in advance of a pandemic. That no longer stands. Researchers can make bird flu vaccines in other ways, but mRNA vaccines are developed much more quickly because they don't rely on finicky biological processes, such as growing elements of vaccines in chicken eggs or cells kept alive in laboratory tanks. Time matters because flu viruses mutate constantly, and vaccines work better when they match whatever variant is circulating. MORE: 2nd bird flu virus detected in western US. What does this mean for prevention? Developing vaccines within eggs or cells can take 10 months after the genetic sequence of a variant is known, Bright said. And relying on eggs presents an additional risk when it comes to bird flu because a pandemic could wipe out billions of chickens, crashing egg supplies. Decades-old methods that rely on inactivated flu viruses are riskier for researchers and time-consuming. Still the Trump administration invested $500 million into this approach, which was largely abandoned by the 1980s after it caused seizures in children. "This politicized regression is baffling," Bright said. A bird flu pandemic may begin quietly in the U.S. if the virus evolves to spread between people but no one is tested at first. Indeed, the Centers for Disease Control and Prevention's dashboard suggests that only 10 farmworkers have been tested for the bird flu since March. Because of their close contact with cattle and poultry, farmworkers are at highest risk of infection. As with many diseases, only a fraction of people with the bird flu become severely sick. So the first sign that the virus is widespread might be a surge in hospital cases. "We'd need to immediately make vaccines," said Angela Rasmussen, a virologist at the University of Saskatchewan in Canada. The U.S. government could scale up production of existing bird flu vaccines developed in eggs or cells. However, these vaccines target an older strain of H5N1 and their efficacy against the virus circulating now is unknown. In addition to the months it takes to develop an updated version within eggs or cells, Rasmussen questioned the ability of the government to rapidly test and license updated shots, with a quarter of HHS staff gone. If the Senate approves Trump's proposed budget, the agency faces about $32 billion in cuts. Further, the Trump administration's cuts to biomedical research and its push to slash grant money for overhead costs could undermine academic hospitals, rendering them unable to conduct large clinical trials. And its cuts to the CDC and to public health funds to states mean that fewer health officials will be available in an emergency. "You can't just turn this all back on," Rasmussen said. "The longer it takes to respond, the more people die." Researchers suggest other countries would produce bird flu vaccines first. "The U.S. may be on the receiving end like India was, where everyone -- rich people, too -- got vaccines late," said Achal Prabhala, a public health researcher in India at medicines access group AccessIBSA. He sits on the board of a World Health Organization initiative to improve access to mRNA vaccines in the next pandemic. A member of the initiative, the company Sinergium Biotech in Argentina, is testing an mRNA vaccine against the bird flu. If it works, Sinergium will share the intellectual property behind the vaccine with about a dozen other groups in the program from middle-income countries so they can produce it. MORE: 12 months and 70 cases since the first human bird flu infection: Are we any safer? The Coalition for Epidemic Preparedness Innovations, an international partnership headquartered in Norway, is providing funds to research groups developing rapid-response vaccine technology, including mRNA, in South Korea, Singapore and France. And CEPI committed up to $20 million to efforts to prepare for a bird flu pandemic. This year, the Indian government issued a call for grant applications to develop mRNA vaccines for the bird flu, warning it "poses a grave public health risk." Pharmaceutical companies are investing in mRNA vaccines for the bird flu as well. However, Prabhala says private capital isn't sufficient to bring early-stage vaccines through clinical trials and large-scale manufacturing. That's because there's no market for bird flu vaccines until a pandemic hits. Limited supplies means the United States would have to wait in line for mRNA vaccines made abroad. States and cities may compete against one another for deals with outside governments and companies, like they did for medical equipment at the peak of the covid pandemic. "I fear we will once again see the kind of hunger games we saw in 2020," Cameron said. In an email response to queries, HHS communications director Andrew Nixon said, "We concluded that continued investment in Moderna's H5N1 mRNA vaccine was not scientifically or ethically justifiable." He added, "The decision reflects broader concerns about the use of mRNA platforms -- particularly in light of mounting evidence of adverse events associated with COVID-19 mRNA vaccines." Nixon did not back up the claim by citing analyses published in scientific journals. In dozens of published studies, researchers have found that mRNA vaccines against COVID are safe. For example, a placebo-controlled trial of more than 30,000 people in the U.S. found that adverse effects of Moderna's vaccine were rare and transient, whereas 30 participants in the placebo group suffered severe cases of COVID and one died. More recently, a study revealed that three of nearly 20,000 people who got Moderna's vaccines and booster had significant adverse effects related to the vaccine, which resolved within a few months. COVID, on the other hand, killed four people during the course of the study. As for concerns about the heart issue, myocarditis, a study of 2.5 million people who got at least one dose of Pfizer's mRNA vaccine revealed about two cases per 100,000 people. COVID causes 10 to 105 myocarditis cases per 100,000. Nonetheless, HHS Secretary Robert F. Kennedy Jr., who founded an anti-vaccine organization, has falsely called COVID shots "the deadliest vaccine ever made." And without providing evidence, he said the 1918 flu pandemic "came from vaccine research." Politicized mistrust in vaccines has grown. Far more Republicans said they trust Kennedy to provide reliable information on vaccines than their local health department or the CDC in a recent KFF poll: 73% versus about half. Should the bird flu become a pandemic in the next few years, Rasmussen said, "we will be screwed on multiple levels." In axing mRNA contract, Trump delivers another blow to US biosecurity, former officials say originally appeared on
2 hours ago
In axing mRNA contract, Trump delivers another blow to US biosecurity, former officials say
This is a KFF Health News story. The Trump administration's cancellation of $766 million in contracts to develop mRNA vaccines against potential pandemic flu viruses is the latest blow to national defense, former health security officials said. They warned that the U.S. could be at the mercy of other countries in the next pandemic. "The administration's actions are gutting our deterrence from biological threats," said Beth Cameron, a senior adviser to the Brown University Pandemic Center and a former director at the White House National Security Council. "Canceling this investment is a signal that we are changing our posture on pandemic preparedness," she added, "and that is not good for the American people." Flu pandemics killed up to 103 million people worldwide last century, researchers estimate. In anticipation of the next big one, the U.S. government began bolstering the nation's pandemic flu defenses during the George W. Bush administration. These strategies were designed by the security council and the Biomedical Advanced Research and Development Authority at the Department of Health and Human Services, among other agencies. The plans rely on rolling out vaccines rapidly in a pandemic. Moving fast hinges on producing vaccines domestically, ensuring their safety and getting them into arms across the nation through the public health system. The Trump administration is undermining each of these steps as it guts health agencies, cuts research and health budgets and issues perplexing policy changes, health security experts said. Since President Donald Trump took office, at least half of the security council's staff have been laid off or left, and the future of BARDA is murky. The nation's top vaccine adviser, Peter Marks, resigned under pressure in March, citing "the unprecedented assault on scientific truth." Most recently, Trump's clawback of funds for mRNA vaccine development put Americans on shakier ground in the next pandemic. "When the need hits and we aren't ready, no other country will come to our rescue and we will suffer greatly," said Rick Bright, an immunologist and a former BARDA director. Countries that produced their own vaccines in the COVID-19 pandemic had first dibs on the shots. While the United States, home to Moderna and Pfizer, rolled out second doses of mRNA vaccines in 2021, hundreds of thousands of people in countries that didn't manufacture vaccines died waiting for them. The most pertinent pandemic threat today is the bird flu virus H5N1. Researchers around the world were alarmed when it began spreading among cattle in the U.S. last year. Cows are closer to humans biologically than birds, indicating that the virus had evolved to thrive in cells like our own. As hundreds of herds and dozens of people were infected in the U.S., the Biden administration funded Moderna to develop bird flu vaccines using mRNA technology. As part of the agreement, the U.S. government stipulated it could purchase doses in advance of a pandemic. That no longer stands. Researchers can make bird flu vaccines in other ways, but mRNA vaccines are developed much more quickly because they don't rely on finicky biological processes, such as growing elements of vaccines in chicken eggs or cells kept alive in laboratory tanks. Time matters because flu viruses mutate constantly, and vaccines work better when they match whatever variant is circulating. Developing vaccines within eggs or cells can take 10 months after the genetic sequence of a variant is known, Bright said. And relying on eggs presents an additional risk when it comes to bird flu because a pandemic could wipe out billions of chickens, crashing egg supplies. Decades-old methods that rely on inactivated flu viruses are riskier for researchers and time-consuming. Still the Trump administration invested $500 million into this approach, which was largely abandoned by the 1980s after it caused seizures in children. "This politicized regression is baffling," Bright said. A bird flu pandemic may begin quietly in the U.S. if the virus evolves to spread between people but no one is tested at first. Indeed, the Centers for Disease Control and Prevention's dashboard suggests that only 10 farmworkers have been tested for the bird flu since March. Because of their close contact with cattle and poultry, farmworkers are at highest risk of infection. As with many diseases, only a fraction of people with the bird flu become severely sick. So the first sign that the virus is widespread might be a surge in hospital cases. "We'd need to immediately make vaccines," said Angela Rasmussen, a virologist at the University of Saskatchewan in Canada. The U.S. government could scale up production of existing bird flu vaccines developed in eggs or cells. However, these vaccines target an older strain of H5N1 and their efficacy against the virus circulating now is unknown. In addition to the months it takes to develop an updated version within eggs or cells, Rasmussen questioned the ability of the government to rapidly test and license updated shots, with a quarter of HHS staff gone. If the Senate approves Trump's proposed budget, the agency faces about $32 billion in cuts. Further, the Trump administration's cuts to biomedical research and its push to slash grant money for overhead costs could undermine academic hospitals, rendering them unable to conduct large clinical trials. And its cuts to the CDC and to public health funds to states mean that fewer health officials will be available in an emergency. "You can't just turn this all back on," Rasmussen said. "The longer it takes to respond, the more people die." Researchers suggest other countries would produce bird flu vaccines first. "The U.S. may be on the receiving end like India was, where everyone -- rich people, too -- got vaccines late," said Achal Prabhala, a public health researcher in India at medicines access group AccessIBSA. He sits on the board of a World Health Organization initiative to improve access to mRNA vaccines in the next pandemic. A member of the initiative, the company Sinergium Biotech in Argentina, is testing an mRNA vaccine against the bird flu. If it works, Sinergium will share the intellectual property behind the vaccine with about a dozen other groups in the program from middle-income countries so they can produce it. The Coalition for Epidemic Preparedness Innovations, an international partnership headquartered in Norway, is providing funds to research groups developing rapid-response vaccine technology, including mRNA, in South Korea, Singapore and France. And CEPI committed up to $20 million to efforts to prepare for a bird flu pandemic. This year, the Indian government issued a call for grant applications to develop mRNA vaccines for the bird flu, warning it "poses a grave public health risk." Pharmaceutical companies are investing in mRNA vaccines for the bird flu as well. However, Prabhala says private capital isn't sufficient to bring early-stage vaccines through clinical trials and large-scale manufacturing. That's because there's no market for bird flu vaccines until a pandemic hits. Limited supplies means the United States would have to wait in line for mRNA vaccines made abroad. States and cities may compete against one another for deals with outside governments and companies, like they did for medical equipment at the peak of the covid pandemic. "I fear we will once again see the kind of hunger games we saw in 2020," Cameron said. In an email response to queries, HHS communications director Andrew Nixon said, "We concluded that continued investment in Moderna's H5N1 mRNA vaccine was not scientifically or ethically justifiable." He added, "The decision reflects broader concerns about the use of mRNA platforms -- particularly in light of mounting evidence of adverse events associated with COVID-19 mRNA vaccines." Nixon did not back up the claim by citing analyses published in scientific journals. In dozens of published studies, researchers have found that mRNA vaccines against COVID are safe. For example, a placebo-controlled trial of more than 30,000 people in the U.S. found that adverse effects of Moderna's vaccine were rare and transient, whereas 30 participants in the placebo group suffered severe cases of COVID and one died. More recently, a study revealed that three of nearly 20,000 people who got Moderna's vaccines and booster had significant adverse effects related to the vaccine, which resolved within a few months. COVID, on the other hand, killed four people during the course of the study. As for concerns about the heart issue, myocarditis, a study of 2.5 million people who got at least one dose of Pfizer's mRNA vaccine revealed about two cases per 100,000 people. COVID causes 10 to 105 myocarditis cases per 100,000. Nonetheless, HHS Secretary Robert F. Kennedy Jr., who founded an anti-vaccine organization, has falsely called COVID shots"the deadliest vaccine ever made." And without providing evidence, he said the 1918 flu pandemic "came from vaccine research." Politicized mistrust in vaccines has grown. Far more Republicans said they trust Kennedy to provide reliable information on vaccines than their local health department or the CDC in a recent KFF poll: 73% versus about half. Should the bird flu become a pandemic in the next few years, Rasmussen said, "we will be screwed on multiple levels."
